CN112805037A - 包含蒽环类的结合蛋白-毒素缀合物，和其在免疫肿瘤学应用中的用途 - Google Patents

包含蒽环类的结合蛋白-毒素缀合物，和其在免疫肿瘤学应用中的用途 Download PDF

Info

Publication number
CN112805037A
CN112805037A CN201980066701.6A CN201980066701A CN112805037A CN 112805037 A CN112805037 A CN 112805037A CN 201980066701 A CN201980066701 A CN 201980066701A CN 112805037 A CN112805037 A CN 112805037A
Authority
CN
China
Prior art keywords
ser
conjugate
gly
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980066701.6A
Other languages
English (en)
Chinese (zh)
Inventor
U·格劳乌德
R·贝利
L·瓦尔德迈尔
F·普雷托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NBE Therapeutics AG
Original Assignee
NBE Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NBE Therapeutics AG filed Critical NBE Therapeutics AG
Publication of CN112805037A publication Critical patent/CN112805037A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980066701.6A 2018-10-11 2019-10-11 包含蒽环类的结合蛋白-毒素缀合物，和其在免疫肿瘤学应用中的用途 Pending CN112805037A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18199879.0 2018-10-11
EP18199879.0A EP3636284A1 (en) 2018-10-11 2018-10-11 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
PCT/EP2019/077644 WO2020074724A1 (en) 2018-10-11 2019-10-11 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications

Publications (1)

Publication Number Publication Date
CN112805037A true CN112805037A (zh) 2021-05-14

Family

ID=63833918

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980066701.6A Pending CN112805037A (zh) 2018-10-11 2019-10-11 包含蒽环类的结合蛋白-毒素缀合物，和其在免疫肿瘤学应用中的用途

Country Status (12)

Country Link
US (1) US20210379194A1 (https=)
EP (2) EP3636284A1 (https=)
JP (1) JP7607556B2 (https=)
KR (1) KR20210075085A (https=)
CN (1) CN112805037A (https=)
AU (1) AU2019358518A1 (https=)
BR (1) BR112021006269A2 (https=)
CA (1) CA3112848A1 (https=)
EA (1) EA202190653A1 (https=)
MX (1) MX2021003136A (https=)
PH (1) PH12021550750A1 (https=)
WO (1) WO2020074724A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
WO2023217227A1 (zh) 2022-05-12 2023-11-16 先声再明医药有限公司 喜树碱类衍生物及配体-药物偶联物
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
SG11201705041WA (en) 2014-12-23 2017-07-28 Nbe-Therapeutics Ag Binding protein drug conjugates comprising anthracycline derivatives
WO2016128410A1 (en) 2015-02-09 2016-08-18 Nbe Therapeutics Ag Maytansine-drug conjugates of her- 2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
EA201891066A1 (ru) 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ Антитела к ror1
US20190112385A1 (en) 2015-10-30 2019-04-18 Nbe-Therapeutics Ag Anti-mesothelin antibodies
WO2017127702A1 (en) * 2016-01-20 2017-07-27 The Scripps Research Institute Ror2 antibody compositions and related methods
SG11201806120WA (en) * 2016-01-20 2018-08-30 Scripps Research Inst Ror1 antibody compositions and related methods
WO2017125815A2 (en) * 2016-01-22 2017-07-27 MabQuest SA Immunological reagents
CA3035806A1 (en) * 2016-09-07 2018-03-15 University Of Canberra Lysine specific histone demethylase-1 inhibitors and uses therefor
WO2018103739A1 (zh) * 2016-12-09 2018-06-14 凯惠科技发展(上海)有限公司 抗体药物偶联物、制备方法、中间体、药物组合物及应用
KR102771835B1 (ko) * 2017-06-20 2025-02-26 비바솔, 인코포레이티드. Cd38 항체 약물 접합체
WO2019016381A1 (en) * 2017-07-20 2019-01-24 Nbe-Therapeutics Ag MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES
WO2019016392A1 (en) 2017-07-20 2019-01-24 Nbe-Therapeutics Ag HUMAN ANTIBODIES BINDING TO ROR2
EP3665193A1 (en) 2017-08-07 2020-06-17 NBE Therapeutics AG Anthracycline-based antibody drug conjugates having high in vivo tolerability
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules

Also Published As

Publication number Publication date
EA202190653A1 (ru) 2021-05-26
KR20210075085A (ko) 2021-06-22
AU2019358518A1 (en) 2021-04-08
JP2022512672A (ja) 2022-02-07
US20210379194A1 (en) 2021-12-09
PH12021550750A1 (en) 2022-02-21
JP7607556B2 (ja) 2024-12-27
CA3112848A1 (en) 2020-04-16
MX2021003136A (es) 2021-08-19
EP3863681A1 (en) 2021-08-18
BR112021006269A2 (pt) 2021-08-10
EP3636284A1 (en) 2020-04-15
WO2020074724A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
JP6609724B1 (ja) 抗ヒト４−１ｂｂ抗体およびその使用
JP6847037B2 (ja) 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
JP2022130393A (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
CN112805037A (zh) 包含蒽环类的结合蛋白-毒素缀合物，和其在免疫肿瘤学应用中的用途
KR20210013165A (ko) GUCY2c에 특이적인 항체 및 이의 용도
CN110945024B (zh) Lrig-1蛋白特异性结合分子及其用途
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
ES2737307T3 (es) Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer
TW201932491A (zh) 抗４－１ｂｂ抗體、其抗原結合片段及其醫藥用途
AU2022229356A1 (en) Antibodies against claudin-6 and uses thereof
TW202124452A (zh) 抗tigit的新型抗體
CN113227148A (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN113727731B (zh) 靶向pd-1和lag-3的双特异性抗体
KR20240026185A (ko) 항-cd40 항체, 항원 결합 단편 및 이의 의학적 용도
KR20190117467A (ko) IFN-γ-유도성 조절 T 세포 전환가능 항암 (IRTCA) 항체 및 그의 용도
KR20250108093A (ko) Msln에 대한 항체 및 이의 사용 방법
EA051856B1 (ru) Конъюгаты связывающего белка с токсином, содержащие антрациклины, и их применение в иммуноонкологических целях
RU2777573C2 (ru) Антитела против 4-1bb человека и их применение
KR20260042482A (ko) 항-pd-1/ctla-4/tigit 삼중특이성 항체 및 이의 용도
KR20250114286A (ko) 개과 악성종양에 대한 면역제
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
TW201827070A (zh) 合成多肽、含該多肽的組合物、由其產生的抗體及其用途
HK40007669A (en) IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF
HK40008251A (en) Anti-pcna monoclonal antibodies and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination